The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1-4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.

中文翻译：

---

针对非小细胞肺癌：除表皮生长因子突变和间变性淋巴瘤激酶融合以外的驱动子突变。

鉴定表皮生长因子受体，间变性淋巴瘤激酶，BRAF和ROS1基因中的驱动子突变以及随后激酶抑制剂的成功临床开发，不仅显着改善了临床结果，而且还促进了非小细胞肺癌中其他新型驱动子突变的发现癌症。这些驱动子突变可分类为激酶结构域内或附近的突变，基因扩增或融合。在这篇综述中，将讨论BRAF V600E，EGFR和HER-2外显子20突变，FGFR1-4，K-RAS，MET，神经调节蛋白-1，NRTK，PI3K / AKT / mTOR，RET和ROS1基因畸变及其治疗方法。